Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

BeiGene, BioAtla in deal for conditionally activated CTLA-4 inhibitor

April 9, 2019 1:59 PM UTC

BioAtla granted BeiGene a license to BA3071 (CAB-CTLA-4), a conditionally activated inhibitor of CTLA-4, that the partners will develop jointly to treat cancer. The companies plan to test the mAb as monotherapy and in combination with tislelizumab, BeiGene's antibody targeting PD-1.

BioAtla LLC (San Diego, Calif.) will receive $20 million up front and is eligible for undisclosed early clinical milestones, plus $249 million in subsequent milestones. BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) will receive a co-exclusive license with BioAtla for development and manufacturing of the candidate, and an exclusive, worldwide license to commercialize it globally...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article